# Inkef

> Inkef is a VC fund in Amsterdam backing Biotechnology and Health Care. See 89 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Amsterdam, The Netherlands
- Total investments: 89
- Last investment: Jul 2026
- Lead investor: 48%
- Fund size: $585M
- Last fund: Sep 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/inkef
- Website: https://www.inkefcapital.com

Inkef is a venture capital firm based in Amsterdam, backing promising early stage companies in Europe. Inkef takes pride in being a patient, long-term investor with the ability to support companies through several rounds of funding. From the early stages of a technology or life science venture, Inkef supports entrepreneurs building their ideas intosuccessful international businesses.Investment areas: Technology and Healthcare

## Contacts

5 contacts available for Inkef. Shizune tracks 6 team members at Inkef. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/inkef-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.8M–$24M |
| Series A | $3.2M–$42M |
| Series B | $8.2M–$86M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 20 | 22% |
| Health Care | 13 | 15% |
| Medical | 10 | 11% |
| Therapeutics | 10 | 11% |
| Pharmaceutical | 9 | 10% |

72 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 33 | 37% |
| Series B | 18 | 20% |
| Seed | 7 | 8% |
| Funding Round | 6 | 7% |
| Series C | 4 | 4% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 29 | 33% |
| United States | 8 | 9% |
| Germany | 4 | 4% |
| Belgium | 2 | 2% |
| Denmark | 2 | 2% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Frank Lansink | Partner | 2 | https://shizune.co/investors/profile/frank-lansink |
| Thijs Cohen Tervaert | Partner | 3 | https://shizune.co/investors/profile/thijs-cohen-tervaert |
| Derk Arts | Founder | 0 | https://shizune.co/investors/profile/derk-arts-c179 |
| Ivan Burkov | Principal | 2 | https://shizune.co/investors/profile/ivan-burkov |
| Simone Botti | Partner | 4 | https://shizune.co/investors/profile/simone-botti |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Provable Markets | Provable Markets is a financial services company that offers market participants a secure, unified, and pragmatic access point for cash and synthetic equity finance trading. The company has developed an SEC registered Alternative Trading System (ATS) named Aurora. Provable Markets aims to create a paradigm shift in how financial markets operate,with a focus on transparency and solving some of the biggest challenges in the financial industry. The company has a community of passionate people working towards these goals. |  | Series B | Jul 29, 2026 |  |
| Quantum Motion | Quantum Motion Technologies is building a universal quantum computer in Silicon, using CMOS compatible processes. | $163.5M | Series C | May 07, 2026 |  |
| Silverflow | Silverflow is a payment processing technology company that provides direct card-network access to payment service providers. Its cloud-based processing platform provides an upgrade for payment providers to accelerate technological innovation. With Silverflow, PSPs can now directly access card networks, instantly add new functionality, havereal-time insight into transaction fees, and get smart data directly from the networks – all to better serve their merchants.Silverflow was founded in 2019 and is headquartered in Amsterdam, Netherlands. | $40M | Series B | Mar 04, 2026 |  |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| Salvia BioElectronics | Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $60.1M | Series B | May 27, 2025 |  |
| Draupnir Bio | Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases. | $13.2M | Seed | Jul 17, 2024 |  |
| iOnctura | iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M | Series B | Jun 20, 2024 |  |
| Provable Markets | Provable Markets is a financial services company that offers market participants a secure, unified, and pragmatic access point for cash and synthetic equity finance trading. The company has developed an SEC registered Alternative Trading System (ATS) named Aurora. Provable Markets aims to create a paradigm shift in how financial markets operate,with a focus on transparency and solving some of the biggest challenges in the financial industry. The company has a community of passionate people working towards these goals. | $8M | Series A | May 08, 2024 |  |
| Onward | Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI). | $21.9M | Post-IPO Equity | Mar 20, 2024 |  |
| Silverflow | Silverflow is a payment processing technology company that provides direct card-network access to payment service providers. Its cloud-based processing platform provides an upgrade for payment providers to accelerate technological innovation. With Silverflow, PSPs can now directly access card networks, instantly add new functionality, havereal-time insight into transaction fees, and get smart data directly from the networks – all to better serve their merchants.Silverflow was founded in 2019 and is headquartered in Amsterdam, Netherlands. | $16.3M | Series A | Nov 16, 2023 |  |

10 of 89 investments shown.

## Co-investors
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 12 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 8 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 6 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 6 deals together
- [Jeito Capital](https://shizune.co/investors/profile/jeito-capital) — VC Fund, 6 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)
- [Health Care VC Funds in Switzerland](https://shizune.co/investors/health-care-vc-funds-switzerland)
- [Medical Device Investors in Switzerland](https://shizune.co/investors/medical-device-investors-switzerland)

## FAQ

### What does Inkef invest in?

Inkef invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 89 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Inkef's check size?

Inkef typically joins rounds of $2.8M–$24M at Seed, $3.2M–$42M at Series A and $8.2M–$86M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Inkef participates in.

### How do I contact Inkef?

Public channels for Inkef include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Inkef?

The team at Inkef includes Frank Lansink (Partner), Thijs Cohen Tervaert (Partner) and Derk Arts (Founder), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co